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Background: Due to time-dependent confounding by blood pressure and differential loss to follow-up, it is difficult
to estimate the effectiveness of aggressive versus conventional antihypertensive combination therapies in
non-randomized comparisons.
Methods: We utilized data from 22,576 hypertensive coronary artery disease patients, prospectively enrolled in the
INternational VErapamil-Trandolapril STudy (INVEST). Our post-hoc analyses did not consider the randomized
treatment strategies, but instead defined exposure time-dependently as aggressive treatment (≥3 concomitantly
used antihypertensive medications) versus conventional treatment (≤2 concomitantly used antihypertensive
medications). Study outcome was defined as time to first serious cardiovascular event (non-fatal myocardial
infarction, non-fatal stroke, or all-cause death). We compared hazard ratio (HR) estimates for aggressive vs.
conventional treatment from a Marginal Structural Cox Model (MSCM) to estimates from a standard Cox model.
Both models included exposure to antihypertensive treatment at each follow-up visit, demographics, and baseline
cardiovascular risk factors, including blood pressure. The MSCM further adjusted for systolic blood pressure at each
follow-up visit, through inverse probability of treatment weights.
Results: 2,269 (10.1%) patients experienced a cardiovascular event over a total follow-up of 60,939 person-years.
The HR for aggressive treatment estimated by the standard Cox model was 0.96 (95% confidence interval
0.87-1.07). The equivalent MSCM, which was able to account for changes in systolic blood pressure during
follow-up, estimated a HR of 0.81 (95% CI 0.71-0.92).
Conclusions: Using a MSCM, aggressive treatment was associated with a lower risk for serious cardiovascular
outcomes compared to conventional treatment. In contrast, a standard Cox model estimated similar risks for
aggressive and conventional treatments.
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Figure 1 Directed acyclic graph illustrating time-dependent
confounding by blood pressure in the treatment of hypertension.
Abbreviations:→, causal effect; BP0, blood pressure at time 0; BP1,
blood pressure at time 1; T0, antihypertensive treatment at time 0;
T1, antihypertensive treatment at time 1; Y, cardiovascular event.
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Antihypertensive therapy commonly involves multi-drug
treatment strategies that are initiated and continuously
adapted based on clinical characteristics, blood pressure
response, and adverse drug reactions. Due to the com-
plexity of such treatment regimens with respect to drug
combinations and doses, evidence from randomized
controlled trials (RCTs) is often insufficient to inform
common clinical decisions in antihypertensive therapy.
There has been increasing interest in the question of
whether combination antihypertensive therapies lead to
improved clinical outcomes [1-4]. Furthermore, emer-
ging evidence suggests the benefit of aggressive therapy
may be limited to those in specific high risk groups,
[5,6] which makes the focus on such populations, such
as elderly patients with prevalent coronary artery disease
(CAD), of particular interest.
Observational studies, including post hoc analyses of
RCTs, are well suited to supplement the evidence base
from RCTs, at least until a RCT is conducted to more
carefully test the effect of aggressive therapy in clinically
important sub-populations [1]. However, concerns exist
that findings from such nonrandomized studies may be
biased due to confounding by blood pressure and other
clinical characteristics. For example, because more ag-
gressive combination treatments are more likely to be
initiated in patients with uncontrolled blood pressure, it
is likely that the beneficial treatment effects of such
combination therapies will be underestimated. This po-
tential underestimation occurs because uncontrolled
blood pressure simultaneously increases the likelihood
of treatment with aggressive antihypertensive therapy
and risk for adverse clinical outcomes.
To avoid such bias caused by potential confounding fac-
tors, observational studies routinely adjust for baseline
confounding variables. However, in the case of hyperten-
sion and its step-up therapy protocols, the problem is com-
plicated as both treatment (antihypertensive drugs) and
confounder (blood pressure) can change over time (are
time-dependent) and the confounder acts as an important
mediating variable through which the treatment exerts its
beneficial effect. In the presence of this type of time-
dependent confounding, standard methods of confounder
adjustment do not produce unbiased estimates [7].
Figure 1 illustrates the theoretical foundation of the
type of time-dependent confounding described above.
Let blood pressure (BP) be a time-dependent confoun-
der, T be the time-dependent treatment (e.g., antihyper-
tensive drug treatment of varying intensity) and Y be the
outcome (e.g., a cardiovascular event), with subscripts 0
and 1 denoting two time points during follow-up. If
blood pressure, the time dependent confounder, is not
controlled for in the analysis, then blood pressure at
time 1 confounds the association of treatment at time 1with the outcome, because it simultaneously affects both
treatment at time 1 and the risk for a cardiovascular
event. Thus, any estimate of the association of antihy-
pertensive treatment with the risk for cardiovascular
events would be biased if blood pressure is not con-
trolled for. However, if blood pressure is controlled in
the analysis through conventional statistical methods,
then blood pressure at time 1, a variable in the causal
path of the effect of antihypertensive treatment at time 0
on cardiovascular event risk, is adjusted for, again,
resulting in a biased estimate of the causal effect of anti-
hypertensive treatment on cardiovascular event risk.
While conventional statistical models fail to produce un-
biased estimates under these conditions, marginal struc-
tural models (MSMs), first introduced by Robins et al.,
are designed to produce unbiased estimates in the pres-
ence of time-dependent confounding [7].
Previous studies have applied MSMs to similar pro-
blems in other clinical areas, including arthritis, cardio-
vascular disease, and HIV [8-10]. The utility of MSMs
has also been examined in the context of hypertension,
[11,12] providing empirical support for the claim that a
MSM approach is appropriate for observational studies
of antihypertensive medication use.
This study aims to estimate the effect of aggressive (≥3
concomitant antihypertensive drugs) vs. conventional
(≤2 concomitant antihypertensive drugs) antihypertensive
therapy on serious adverse cardiovascular outcomes in the
22,576 patients enrolled in the INternational VErapamil-
Trandolapril STudy (INVEST) using a Marginal Structural
Cox Model (MSCM) to account for time-dependent con-
founding by systolic blood pressure and differential loss to
follow-up over the course of the study. By comparing the
results of the MSCM to the results of a standard Cox
model, we aim to determine the extent of bias that might
be introduced by the use of standard methods.
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Study population
The present investigation is a post-hoc analysis of data
from INVEST, a large, international, randomized con-
trolled hypertension treatment trial that enrolled
patients with hypertension and coronary artery disease
(CAD) between January 1998 and February 2001. Details
of the design, rationale and results have been previously
published [13,14]. Briefly, after an extensive cardiovascu-
lar history and physical exam, 22,576 CAD patients
≥50 years old were randomly assigned to either a verap-
amil SR- or an atenolol-based multidrug antihyperten-
sive strategy. Trandolapril and hydrochlorothiazide
(HCTZ) were specified as added agents, if needed for
blood pressure control, with trandolapril added first in
the verapamil SR strategy and HCTZ added first in the
atenolol strategy. In both strategies, trandolapril was
recommended for organ protection among patients with
heart failure, diabetes, or renal impairment. Follow-up
continued until a patient was lost to follow-up, died, or
the end of the study. A total of 61,835 patient-years were
accumulated and both strategies provided excellent
blood pressure control (>70% of patients achieved blood
pressure <140/90 mm Hg) with no difference in mean
blood pressure between treatment strategies at any of
the follow-up visit time points. Additionally, there was
no significant difference between the strategies in pre-
venting the primary outcome (hazard ratio 0.98, 95%
confidence interval 0.90-1.06), which was the first occur-
rence of all-cause death, nonfatal myocardial infarction
(MI), or nonfatal stroke. For the present analyses,
patients from both treatment strategies were combined.
The protocol was conducted in accordance with principles
outlined in the Declaration of Helsinki, and institutional
review boards and ethics committees at participating sites
approved the protocol. All patients provided written
informed consent.
Study variables
During follow-up, the protocol directed scheduled visits
every six weeks for the first six months and every six
months until the last patient enrolled was followed for
two years. To decrease visit burden, patients with con-
trolled blood pressure at visits 2 and 3 were allowed to
skip visit 4 and then be seen at visit 5. The largest pos-
sible number of visits included in this analysis was 14.
At each visit, patients were assessed for occurrence of
adverse events, and response to treatment. If patients
did not return for one or multiple protocol visits, values
for study variables (e.g., systolic blood pressure, antihy-
pertensive drug use) were carried forward from the last
available visit. If a patient was lost to follow-up (i.e., did
not have another visit or final assessment), the patient
was censored at the time of the last visit.Exposure
Antihypertensive drug use was recorded at each visit for
all study- (atenolol, verapamil, HCTZ, trandolapril) and
non-study antihypertensive drugs (all other antihyper-
tensive drugs). For this study, both study and non-study
antihypertensive drugs were included in the analysis. At
each visit, we defined aggressive and conventional treat-
ment as simultaneous exposure to ≥3 and ≤2 antihyper-
tensive medications, respectively. This definition was
chosen empirically based on the average number of anti-
hypertensive drugs used in INVEST which, depending
on study visit, ranged between two and three [14]. To
assess robustness of our results in regards to this expos-
ure definition, two sensitivity analyses were conducted
that defined aggressive treatment as ≥4 (vs. ≤3) and ≥2
(vs. ≤1) concurrently used antihypertensive drugs.
Outcome
The primary outcome for the present analysis is the
same as that used by the original INVEST protocol, and
was defined as the first occurrence of all-cause death,
nonfatal MI, or nonfatal stroke. All components of this
composite outcome were fully adjudicated by an inde-
pendent end point committee.
Covariates
Baseline covariates included in the analysis include age,
sex, race/ethnicity, randomized treatment strategy, and
baseline history of myocardial infarction, stroke/transi-
ent ischemic attack, congestive heart failure, diabetes,
renal impairment, peripheral vascular disease, CABG/
PCI, or smoking [15]. Blood pressure was measured
twice, at least 2 minutes apart, at each visit with a stand-
ard mercury sphygmomanometer in a sitting position.
[16] In a given patient throughout the trial all measure-
ments were taken on the same arm, and, when possible,
approximately the same time of day to minimize diurnal
variation and measurement error. Only systolic blood
pressure was included in this analysis. Because of the
J-shaped relationship between systolic blood pressure
and the risk for cardiovascular outcomes in INVEST,
[17-19] systolic blood pressure was categorized into
three categories, tight control (<120 mm Hg), usual con-
trol (120 mm Hg to <140 mm Hg), and not controlled
(≥ 140 mm Hg).
Statistical methods
The effect of aggressive antihypertensive treatment on
the risk of the primary outcome was assessed adjusted
for time-dependent systolic blood pressure using a Cox
proportional hazards regression with combined stabi-
lized weights (i.e., a marginal structural Cox model), as
well as unadjusted for time-dependent systolic blood
pressure using a Cox proportional hazards regression
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model).
Marginal structural models
MSMs use inverse probability of treatment weights
(IPTWs) and inverse probability of censoring weights
(IPCWs) to create a pseudo-population in which treat-
ment is un-confounded by subject specific characteris-
tics and no censoring occurs [10]. MSMs are fitted in a
two-stage process. The first step estimates the individual
IPTWs and IPCWs. The IPTWs are based on each
subject’s probability of having their own treatment his-
tory at each time point given the subject’s covariates
(including time-dependent covariates). The IPCWs are
similarly estimated based on each subject’s probability
at each time point to be censored based on his or her
covariates. The second step uses the IPTWs and
IPCWs as weights in a regression model of the effect
of the treatment on the outcome. Because of the
weighting, the regression now takes place in the
pseudo-population and results — under the assumption
of no unmeasured confounding and correct model spe-
cifications — in a causal estimate of the treatment’s ef-
fect on the study outcome.
For this study, a MSCM was used to estimate the
association between time-dependent antihypertensive
treatment (aggressive vs. conventional treatment) on
the primary outcome, controlling for systolic blood
pressure at each visit. First, stabilized IPTWs and
IPCWs were estimated, as stabilized weights have been
shown to produce narrower confidence intervals with
better coverage rates than unstablized weights [7,10].
The IPTWs were estimated using a pooled logistic re-
gression model for the probability of being exposed to
aggressive versus standard antihypertensive therapy at
visit (k) conditional on select baseline covariates and
systolic blood pressure (tight control, usual control,
not controlled) at baseline, visit (k) and visit (k-1).
The IPCWs were estimated in the same fashion using
a pooled logistic regression model for the probability
of being censored at visit (k). Lastly, combined stabi-
lized weights were computed by multiplying the IPTW
and IPCW for each patient visit and used in a
weighted Cox proportional hazards model. To over-
come computational limitations of standard software
which cannot typically handle time-varying weights in
Cox proportional hazards models, the hazard ratio was
estimated by fitting a pooled logistic regression model
that included the weights, baseline covariates and the
time-dependent antihypertensive treatment variable.
[10,20] SAS 9.1 (SAS Institute, Carey, NC) was used
for data management and analysis. SAS code provided
by Hernan et al. was adapted and used to fit the
MSCMs for our study [10]. This approach required abinary independent variable, assumed that, once
started, aggressive treatment was continued until cen-
soring, and assumed that observations were equally
spaced.Time-dependent Cox proportional hazards models
We also estimated the hazard ratio for aggressive vs.
conventional antihypertensive treatment with a standard
time-dependent Cox model using the same pooled logis-
tic regression model that was used in the MSCM above
but without inverse probability weighting. The hazard
ratio obtained by the conventional time-dependent Cox
model was then compared to the one obtained from the
MSCM to determine the magnitude of the potential
confounding effect of systolic blood pressure on the haz-
ard ratio for aggressive vs. conventional antihypertensive
treatment.Results
The 22,576 patients enrolled in INVEST accrued a total
of 61,845 patient years of follow up, with 2,269 patients
experiencing a primary outcome event during this
period. For the present investigation, 906 patient years
of follow-up were excluded because they accrued after
the occurrence of a nonfatal primary outcome event and
thus, a total of 60,939 patient years of follow-up
remained available for analysis. Baseline characteristics
are summarized in Table 1.
Table 2 provides an inverse probability of treatment
and censoring weighted estimate for the effect of ag-
gressive (≥3 concurrent antihypertensive drugs) versus
conventional (≤2 concurrent antihypertensive drugs)
antihypertensive treatment, compared with estimates
from the equivalent standard time-dependent Cox
model. The standard Cox model estimated no statisti-
cally significant difference in the primary outcome
comparing treatment with aggressive vs. conventional
antihypertensive treatment (HR 0.96, 95% CI 0.87-1.07).
In contrast, the MSCM estimated a statistically signifi-
cant 19% (HR 0.81, 95% CI 0.71-0.92) reduction in the
hazard for the primary outcome for patients treated
with aggressive antihypertensive therapy as compared
with conventional therapy.
Table 2 also shows the results of two sensitivity ana-
lyses conducted to assess whether our results are stable
across additional exposure definitions. Across all expos-
ure definitions, the MSCM consistently estimated a lar-
ger beneficial effect for aggressive treatment than the
standard Cox model. The between-model differences
(MSCM vs. standard Cox model) in HR estimates grew
in magnitude (from 0.06 to 0.19) as the number of con-
comitant drugs required for the aggressive treatment
definition increased from ≥2 to ≥4.











Verapamil SR Strategy 11267 (49.9)
Atenolol Strategy 11309 (50.1)
History of
Myocardial infarction 7218 (32.0)
Stroke/transient ischemic attack 1629 (7.2)
Congestive Heart Failure (class I-III) 1256 (5.6)
Diabetes† 6400 (28.4)
Renal impairment{ 424 (1.9)
Peripheral vascular disease 2699 (12.0)
CABG or PCI 6166 (27.3)
Smoking (ever) 10454 (46.3)
Blood Pressure Systolic Blood Pressure, mean (SD) 149.5 (19.7)
Diastolic Blood Pressure, mean (SD) 86.3 (12.0)
Heart Rate, mean (SD), beats/min 75.5 (9.5)
Abbreviations: SD, Standard deviation; CABG, Coronary artery bypass graft; PCI,
percutaneous coronary interventions.
Unless indicated otherwise, values express numbers (percentage).
†History of or currently taking antidiabetic medications.
{History of or currently have elevated serum creatinine level but less than
4 mg/dl (354 μmol/L).
Table 2 Effect of aggressive antihypertensive treatment
on INVEST primary outcome: Estimates from a marginal












































Standard Cox model 0.98 0.90-1.07
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Our findings suggest that in hypertensive patients with
CAD, aggressive antihypertensive therapy is associated
with reduced risk for adverse cardiovascular outcomes
compared with more conventional treatment. This effect
was only apparent when using a MSCM that adjusted for
time-dependent confounding by systolic blood pressure
and differential loss to follow-up, not when a standard
Cox model was used. This suggests that time-dependent
confounding by systolic blood pressure and/or differen-
tial loss to follow-up introduces bias into the estimates of
treatment effects for antihypertensive combination ther-
apies resulting in an under-estimation of the benefits of
more aggressive treatment regimens. Similar findings
were observed across the two additional exposure specifi-
cations used in sensitivity analysis. However, the
observed differences between the MSCMs and standard
Cox models did not rise to statistical significance in two
out of the three exposure specifications. The magnitude
of the between model differences increased with thenumber of concomitant drugs required for the aggressive
treatment definition, suggesting that time-dependent
confounding by blood pressure may be of increasing
concern the more aggressive the examined treatment
strategy becomes.
Assuming a correctly specified model and no violation
of the underlying model assumptions, the MSCM esti-
mate for the effect of aggressive versus conventional
antihypertensive therapy is interpretable as the effect
that would have been observed in a RCT that compared
the effects of aggressive to conventional treatment with-
out making any adjustments in therapy to assure blood
pressure control. In the absence of direct experimental
evidence on treatment intensity, our results thus suggest
that more aggressive treatment strategies are beneficial
in adults older than 50 years with hypertension and
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clinical utility as antihypertensive therapy in practice, as
well as in typical RCTs, is highly dynamic (i.e., routinely
adjusted to achieve and maintain target blood pressure
goals) while our analysis makes inferences about a static
treatment comparison. Our findings also need to be ap-
plied in the context of the known fact that more com-
plex treatment regimens generally result in lower
adherence [21] and increased risk of adverse effects [22].
Our results are consistent with other studies that
have considered blood pressure as a mediating, time-
dependent confounder [11,12]. Specifically, our results
extend the findings by Sugihara et al. from blood
pressure response to clinical outcomes, and suggest
that aggressive management of hypertension may not
only result in higher achievement rates of target blood
pressure [12] but also in clinically important reduction
in cardiovascular outcomes. In these previous studies,
the use of IPTW to handle time dependent confound-
ing by blood pressure enabled observational analyses
of key associations that were consistent with the asso-
ciations found from RCTs. In contrast, conventional
approaches led to significant amounts of bias in the
estimation of the association between antihypertensive
medications and cardiovascular outcomes [11,12]. The
previous work on this subject as well as the known
theoretical results give us confidence that a MSM ap-
proach is providing the best estimate of the effective-
ness of aggressive antihypertensive therapy and is less
susceptible to bias when compared with standard ana-
lytical approaches.
Of course, there are other possible explanations for the
observed differences between the two approaches. The
estimates from a MSCM are marginal estimates and thus
estimate the contrast between treating everyone and
treating no-one. In contrast, the conventional estimates
are conditional estimates and thus estimate the effect of
treatment holding all other variables constant. In the
presence of non-linear covariates or effect measure
modification, these estimators will be estimating different
parameters which could explain some of the observed
differences. The MSCM approach also accounted for loss
to follow-up (via IPCW) whereas the conventional
approach assumed random censoring.
Importantly, our results do not speak to the mechan-
isms by which aggressive antihypertensive therapy
reduces the risk for cardiovascular outcomes, which may
include both non-blood pressure mediated effects of in-
dividual agents, e.g., heart rate lowering effects of beta
blockers in patients with a history of myocardial infarc-
tion [23], as well as tighter blood pressure control. That
tight blood pressure control might be of benefit to
patients with hypertension and CAD is not unexpected,
as strong evidence suggests that the cardio-protectiveeffects of blood pressure lowering medications are
largely mediated by blood pressure reduction [24-27].
This study illustrates how properly constructed and
appropriately analyzed observational studies can provide
some clinical guidance until direct RCT evidence is
available. Further extensions of this work could aim to
increase clinical utility by using dynamic treatment regi-
mens that consider specific blood pressure thresholds
for aggressive versus conventional treatment to allow
identification of high-risk sub-groups [28,29], as there
has been some evidence that aggressive treatment may
be less effective in some sub-populations [18], and
examine specific drug and drug/dose combinations.
Limitations
The present study has several limitations. First, the
generalizability of our study is limited to hypertensive
patients with CAD. However, this population represents
a large and rapidly growing important high risk popula-
tion that has not been at the center of antihypertensive
research efforts and therefore warrants comprehensive
investigation [30].
Second, measurement error is inherently problematic
in studies of hypertension [31-33]. While the INVEST
protocol tried to minimize measurement error by pro-
viding to all site investigators standardized blood pres-
sure measurement instructions following JNC VI
guidelines [34], some measurement error is unavoidable.
However, it is unlikely that this measurement error
results in important levels of bias and more likely
reduces the precision of the estimates due to additional
random error in the estimates.
Third, we imputed data for missing visits during
follow-up which may result in limited misclassification
of both the exposure and the time-dependent confoun-
der. Such misclassification would likely bias results (ef-
fect estimates of aggressive vs. conventional therapy as
well as differences between the two analytic approaches)
towards the null.
Fourth, to simplify the analytic approach, we focused
the adjustment for time-dependent confounding on sys-
tolic blood pressure, and did not include additional
time-dependent variables such as diastolic blood pres-
sure or heart rate. More complex modeling of multiple
time-dependent confounding factors is an active area for
future research in this field.
The use of a MSCM to adjust for time-dependent con-
founding through inverse probability of treatment and
censoring weighting introduces additional limitations to
the study. MSMs, as implemented in this study, require a
number of assumptions and a rather simple data structure.
First, the independent variable of interest has to be binary.
Our study categorized antihypertensive drug use into ag-
gressive vs. conventional antihypertensive treatment. This
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and/or drug classes nor does it take dosing of each specific
drug into account. If treatment effects vary between spe-
cific drugs and doses, our model will not show these dif-
ferences and rather produce an estimate reflective of the
average treatment combinations used in the aggressive
and conventional treatment groups. Thus, our results do
not address the question of the optimal selection or dosing
of specific antihypertensive drugs for the aggressive ther-
apy regimen.
Second the method requires the assumption, that once
initiated, exposure is not discontinued until the end of
follow-up or censoring (an intention to treat approach to
exposure). This assumption is not fully met in INVEST
using actual medication use. We therefore focused on the
decision to begin aggressive (as opposed to conventional)
treatment as our object of inference rather than an “as
treated” analysis, which likely makes the analysis more
conservative (i.e., introduces a bias towards the null).
Third, the pooled logistic regression model that was
used to estimate the MSCM assumes that observations
are equally spaced, which was not the case in the IN-
VEST where the initial five visits occurred in six week
intervals while the remaining visits occurred in six
month intervals.
Lastly, as discussed in more detail in the introduction,
in the presence of a time-dependent confounder stand-
ard methods allow two options, both expected to result
in biased estimates — to disregard the time-dependent
confounder (and accept the resulting bias introduced by
the time-dependent confounder) or to adjust for the
time-dependent confounder (and introduce bias by
adjusting for a variable on the causal pathway) [7]. Our
study focused on the comparison between the MSCM to
the former standard option, i.e., compared the MSCM to
a standard Cox model that allowed exposure to vary
over time but held all covariates, including systolic blood
pressure, fixed at their baseline value. We chose this
comparison because the standard Cox model with fixed
covariates is more widely used and because its compari-
son to the MSCM provides a direct estimate of the bias
introduced by the time-dependent confounder which is
more readily interpretable than the bias introduced by
inappropriate adjustment (adjustment for a time-
dependent intermediate variable that is affected by prior
treatment). However, the alternative approach (a com-
parison to a standard Cox model that allows both expos-
ure and covariates to change over time) [35] could be
considered fairer as the both approaches ‘adjust’ for the
time-dependent confounder and may, in our example,
have shown better performance in terms of bias. One
should therefore be cautious in generalizing the esti-
mates of bias provided in this paper to scenarios involv-
ing Cox models with time-dependent covariates.Summary and conclusions
It is conceptually clear that differential loss to follow-up
and time-dependent confounding by a surrogate are
problematic for the estimation of treatment effects in
observational studies. Our findings empirically illustrate
this issue by showing that standard Cox models system-
atically underestimate the effectiveness of aggressive
antihypertensive combination treatment in a post-hoc
analysis of a large hypertension treatment RCT and thus
demonstrate the importance of using appropriate meth-
ods to address time-dependent confounding and differ-
ential loss to follow-up in observational antihypertensive
drug studies. Although they do not support inferences
regarding specific mechanisms of action, the results
from a MSCM clearly suggest that more aggressive anti-
hypertensive regimens are associated with a reduced rate
of serious cardiovascular events in patients with hyper-
tension and prevalent CAD.
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